HydroVax-CHIKV: an inactivated chikungunya vaccine for adults
Official title: A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine
Funded at Najit Technologies, INC. · NIH-11142621 · Data updated 2026-11-12
A new inactivated chikungunya vaccine being given to healthy adults to check safety and immune response.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Najit Technologies, INC. NIH-funded |
| Lab location | 1 site (Beaverton, UNITED STATES) |
| Project start | July 1, 2020 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $980,963 |
| NIH project number | 5U44AI152995-03 |
| Project ID | NIH-11142621 on NIH RePORTER |
Who could benefit from this research
✓Could help
Healthy adults aged 21 years and older who can attend study visits and are willing to receive vaccinations and blood draws are the intended participants.
✕Less likely to help
People under age 21, pregnant individuals, those with active chikungunya infection, or people with severe immune suppression are unlikely to benefit from participation in this early-phase vaccine trial.
What this research studies
You would receive either the HydroVax-CHIKV vaccine or a placebo in a randomized, double-blind dose-escalation format and be followed over time. The study includes clinic visits, safety monitoring for adverse events, and blood draws to measure immune responses. This Phase 1 trial is focused on early safety and whether the vaccine prompts antibody responses that could protect against chikungunya. If results are promising, the vaccine could move into larger trials that enroll more people and test protection.
Why it matters
Potential benefit: If successful, this vaccine could provide protection against chikungunya infection and help reduce outbreaks, especially for people in or traveling to affected regions.
How similar studies have gone: Other chikungunya vaccine candidates have produced promising immune responses in early human trials, but no licensed vaccine is yet available.
Where this research is happening
-
Najit Technologies, INC.
Beaverton, United States Active
Researchers
- Principal investigator: Amanna, Ian James — Najit Technologies, INC.
- Study coordinator: Amanna, Ian James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.